These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 35397421)
1. The mechanism of low-dose radiation-induced upregulation of immune checkpoint molecule expression in lung cancer cells. Wan X; Fang M; Chen T; Wang H; Zhou Q; Wei Y; Zheng L; Zhou Y; Chen K Biochem Biophys Res Commun; 2022 Jun; 608():102-107. PubMed ID: 35397421 [TBL] [Abstract][Full Text] [Related]
2. CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50. Ozawa Y; Harutani Y; Oyanagi J; Akamatsu H; Murakami E; Shibaki R; Hayata A; Sugimoto T; Tanaka M; Takakura T; Furuta K; Okuda Y; Sato K; Teraoka S; Ueda H; Tokudome N; Kitamura Y; Fukuoka J; Nakanishi M; Koh Y; Yamamoto N Cancer Sci; 2021 Jan; 112(1):72-80. PubMed ID: 33084148 [TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy. Jin S; Wang H; Li Y; Yang J; Li B; Shi P; Zhang X; Zhou X; Zhou X; Niu X; Wu M; Wu Y; Zhai W; Qi Y; Gao Y; Zhao W Cell Commun Signal; 2024 Mar; 22(1):173. PubMed ID: 38462636 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer. Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075 [TBL] [Abstract][Full Text] [Related]
5. PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer. Yang Z; Peng Y; Guo W; Xu J; Li L; Tian H; Li R; Liu L; Tan F; Gao S; He J Thorac Cancer; 2021 Jun; 12(11):1743-1751. PubMed ID: 33979899 [TBL] [Abstract][Full Text] [Related]
6. Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer. Lang C; Lantos A; Megyesfalvi Z; Egger F; Hoda MA; Mosleh B; Klikovits T; Oberndorfer F; Timelthaler G; Ferencz B; Fillinger J; Schwendenwein A; Querner AS; Boettiger K; Renyi-Vamos F; Hoetzenecker K; Laszlo V; Schelch K; Dome B ESMO Open; 2022 Dec; 7(6):100631. PubMed ID: 36399951 [TBL] [Abstract][Full Text] [Related]
7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
8. PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy. Yang Z; Xu J; Li R; Gao Y; He J J Cancer Res Clin Oncol; 2019 Dec; 145(12):3055-3065. PubMed ID: 31522278 [TBL] [Abstract][Full Text] [Related]
9. Irradiation Suppresses IFNγ-Mediated PD-L1 and MCL1 Expression in EGFR-Positive Lung Cancer to Augment CD8 Wang CI; Chang YF; Sie ZL; Ho AS; Chang JS; Peng CL; Cheng CC Cells; 2021 Sep; 10(10):. PubMed ID: 34685495 [TBL] [Abstract][Full Text] [Related]
10. Targeting CD47 enhanced the antitumor immunity of PD-L1 blockade in B-cell lymphoma. Nan Y; Zhang X; Wang S; Xu C; Wang Y; Han L; Luan J; Hu X; Chen W; Cao Z; Zhu Z; Zeng X; Fan J; Ye L; Shi X; Ju D Immunotherapy; 2023 Feb; 15(3):175-187. PubMed ID: 36727256 [TBL] [Abstract][Full Text] [Related]
11. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616 [TBL] [Abstract][Full Text] [Related]
12. Orexin A Suppresses the Expression of Exosomal PD-L1 in Colon Cancer and Promotes T Cell Activity by Inhibiting JAK2/STAT3 Signaling Pathway. Wen J; Chang X; Bai B; Gao Q; Zhao Y Dig Dis Sci; 2022 Jun; 67(6):2173-2181. PubMed ID: 34097168 [TBL] [Abstract][Full Text] [Related]
13. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment. Wang R; Zhang C; Cao Y; Wang J; Jiao S; Zhang J; Wang M; Tang P; Ouyang Z; Liang W; Mao Y; Wang A; Li G; Zhang J; Wang M; Wang S; Gui X Theranostics; 2023; 13(1):148-160. PubMed ID: 36593962 [No Abstract] [Full Text] [Related]
14. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. Lian S; Xie R; Ye Y; Xie X; Li S; Lu Y; Li B; Cheng Y; Katanaev VL; Jia L EBioMedicine; 2019 Apr; 42():281-295. PubMed ID: 30878596 [TBL] [Abstract][Full Text] [Related]
15. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway. Wen Z; Sun H; Zhang Z; Zheng Y; Zheng S; Bin J; Liao Y; Shi M; Zhou R; Liao W Cancer Commun (Lond); 2023 May; 43(5):562-581. PubMed ID: 37031362 [TBL] [Abstract][Full Text] [Related]
16. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling. Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127 [TBL] [Abstract][Full Text] [Related]
17. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway. Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877 [TBL] [Abstract][Full Text] [Related]
18. Hypoxia and acidity regulate immune checkpoint molecule and IFN-β expression in non-small cell lung cancer cell lines. Mitrakas AG; Giatromanolaki A; Koukourakis MI J Recept Signal Transduct Res; 2023 Dec; 43(2):31-36. PubMed ID: 37099383 [TBL] [Abstract][Full Text] [Related]
19. Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma. Yang P; He S; Ye L; Weng H Int Arch Allergy Immunol; 2024; 185(9):910-920. PubMed ID: 38781935 [TBL] [Abstract][Full Text] [Related]
20. Breast cancer cells promote CD169 Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]